Less Haste, More Speed, More Science: Lessons to be Learned from COVID-19 Studies.
作者信息
Singer Mervyn
机构信息
Intensive Care Medicine University College London London, United Kingdom.
出版信息
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1258-1260. doi: 10.1164/rccm.202203-0617ED.
Abstract
摘要
相似文献
1
Less Haste, More Speed, More Science: Lessons to be Learned from COVID-19 Studies.欲速则不达，科学更重要：从新冠病毒研究中汲取的教训
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1258-1260. doi: 10.1164/rccm.202203-0617ED.
2
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.针对严重急性呼吸系统综合征冠状病毒 2 刺突受体结合蛋白的中和单克隆抗体 CT-P59 的安全性、病毒学疗效和药代动力学：两项在健康个体和轻度严重急性呼吸系统综合征冠状病毒 2 感染患者中进行的随机、安慰剂对照、I 期研究。
Clin Ther. 2021 Oct;43(10):1706-1727. doi: 10.1016/j.clinthera.2021.08.009. Epub 2021 Aug 23.
3
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.巴伦替尼（Bamlanivimab）对比安慰剂对熟练护理和辅助生活设施居民和工作人员 COVID-19 发病率的影响：一项随机临床试验。
JAMA. 2021 Jul 6;326(1):46-55. doi: 10.1001/jama.2021.8828.
4
Generation and characterization of humanized synergistic neutralizing antibodies against SARS-CoV-2.生成并鉴定针对 SARS-CoV-2 的人源化协同中和抗体。
J Med Virol. 2022 Aug;94(8):3791-3800. doi: 10.1002/jmv.27801. Epub 2022 May 7.
5
Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?替麦利单抗用于治疗多发性硬化症和新冠病毒：它会是一把双刃剑吗？
Mult Scler Relat Disord. 2022 Aug;64:103938. doi: 10.1016/j.msard.2022.103938. Epub 2022 Jun 6.
6
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.在 21 天内启动 COVID-19 单克隆抗体的比较有效性自适应平台试验。
Contemp Clin Trials. 2022 Feb;113:106652. doi: 10.1016/j.cct.2021.106652. Epub 2021 Dec 9.
7
Inflammatory Bowel Disease and the SARS-CoV-2 Pandemic: More Speed, Less Haste.炎症性肠病与新型冠状病毒肺炎大流行：更快行动，勿急行事。
Gastroenterology. 2021 Jan;160(1):473-474. doi: 10.1053/j.gastro.2020.05.013. Epub 2020 May 8.
8
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
9
Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.一名接受奥瑞珠单抗治疗的患者在接种辉瑞新冠疫苗后抗新冠病毒刺突蛋白抗体反应呈阴性
J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.
10
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.成功早期使用抗 SARS-CoV-2 单克隆中和抗体治疗 SARS-CoV-2 感染的血液病患者：一项捷克多中心经验。
Hematol Oncol. 2022 Apr;40(2):280-286. doi: 10.1002/hon.2974. Epub 2022 Feb 17.
本文引用的文献
1
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).一项抗 GM-CSF 单克隆抗体奥替利珠单抗治疗重症 COVID-19 肺炎的随机临床试验（OSCAR）。
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.01870-2021. Print 2023 Feb.
2
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.抗粒细胞-巨噬细胞集落刺激因子单克隆抗体吉西单抗治疗 COVID-19 肺炎：一项随机、双盲、安慰剂对照试验。
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1290-1299. doi: 10.1164/rccm.202108-1859OC.
3
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.伦齐单抗治疗 COVID-19 肺炎住院患者（LIVE-AIR）：一项 3 期、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1.
4
Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids.潜类分析揭示 COVID-19 相关急性呼吸窘迫综合征亚组对皮质类固醇的反应存在差异。
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285. doi: 10.1164/rccm.202105-1302OC.
5
Systemic corticosteroids for the treatment of COVID-19.全身性皮质类固醇治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
6
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
7
Do not just sit there, do something … but do no harm: the worrying aspects of COVID-19 experimental interventions.不要只是干坐在那里，做点什么……但不要造成伤害：新冠病毒实验性干预措施中令人担忧的方面。
Intensive Care Med. 2021 Aug;47(8):896-898. doi: 10.1007/s00134-021-06460-9. Epub 2021 Jul 5.
8
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高：快速系统评价、荟萃分析，并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
9
Immunomodulators in COVID-19: Two Sides to Every Coin.新冠疫情中的免疫调节剂：事物皆有两面性
Am J Respir Crit Care Med. 2020 Nov 15;202(10):1460-1462. doi: 10.1164/rccm.202008-3148LE.
10
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.GM-CSF 疗法治疗 COVID-19：调和对立的治疗方法。
Nat Rev Immunol. 2020 Aug;20(8):507-514. doi: 10.1038/s41577-020-0357-7. Epub 2020 Jun 23.
Zotero 插件